Jiangsu Hengrui Medicine Co., Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Jiangsu Hengrui Medicine Co., Ltd.
China continues with a post-coronavirus approvals rush, granting additional indications to Merck's Keytruda, BI's Ofev and Novo Nordisk's Norditropin.
Several high-profile products including Dupixent gain approvals in China.
China's centralized procurement scheme, if further expanded after causing the prices of 32 drugs to be cut by more than half in the latest round, will leave companies no room to breathe easy amid the already devastating coronavirus outbreak, analysts say.
China insists there is no double standard and won’t tolerate any quality issues in its centralized procurement process.
- Generic Drugs
- Radiopharmaceuticals, Contrast Agents
- Large Molecule